U.S. FDA extends review period for expanded use of Abbvie's arthritis drug – Reuters

U.S. FDA extends review period for expanded use of Abbvie’s arthritis drug – Reuters

The U.S. Food and Drug Administration has extended the review period for expanded use of Abbvie Inc’s rheumatoid arthritis drug Rinvoq by three months, the U.S. drugmaker said on Wednesday.

Read More…

You May Also Like